A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.
KRAS G12D Mutations|Advanced Solid Tumors
DRUG: GFH375
Phase Ia:The incidence and severity of AEs and SAEs, The incidence and severity of AEs and SAEs, 24 months|Phase Ia:The incidence of DLT events, The incidence of DLT events, 21 days|Phase Ib:The incidence and severity of AEs and SAEs, The incidence and severity of AEs and SAEs, 24 months|Phase II:Overall response rate (ORR), Aassessed by investigators according to RECIST 1.1, 24 months
Plasma concentrations, Plasma concentrations and PK parameters of GFH375, up to 21 days|Efficacy endpoints, Duration of response (DoR), 24 months|Efficacy endpoints, Disease control rate (DCR), 24 months|Efficacy endpoints, Progression free survival (PFS), 24 months|Efficacy endpoints, Overall survival (OS), 24 months
This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.